Strategic Partnerships Target opportunities around collaborative research agreements with leading universities and research institutions mentioned as current partners (The University of Texas at Austin and University of Maryland at Baltimore) to co-develop oncology therapeutics and antiviral platforms, leveraging their pipelines to accelerate joint ventures or sponsored research programs.

Diversified Pipeline Monetize the dual focus on oncology and broad-spectrum antivirals by pursuing licensing, co-development, or milestone-based partnerships with pharma companies seeking oncology candidates or antiviral platforms, especially those aiming to address unmet medical needs in cancer and emerging infectious disease.

Early Stage Flexibility Capitalize on the small company profile with a nimble development path by offering strategic collaboration structures such as milestone-driven deals, option rights, or sponsored research, appealing to larger companies seeking to augment their R&D engines without sizable upfront commitments.

Financial Growth Levers Explore licensing those small-molecule anti-cancer therapeutics and antiviral platform technologies to drive upfront fees, co-development funding, and royalties, leveraging recent financing activity and revenue presence to establish credibility with potential partners.

Visible Leadership Additions Leverage recent board appointments to highlight governance strength and strategic direction for potential buyers or partners, using leader credibility to accelerate due diligence and partnerships in both oncology and antiviral domains.